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Background
The naturally occurring oncolytic virus, reovirus, exhi-
bits cytotoxic effects on cancer cells. Reovirus is safe,
and currently is in multiple clinical trials testing for the
treatment of different cancers. NK cells are innate
immune effectors that mediate antibody dependent cel-
lular cytotoxicity (ADCC) against tumor cells.
Methods
Here we investigated the direct effect of reovirus on NK
cell mediated ADCC against the EGFR (Epidermal Growth
Factor) positive colorectal cancer cell line: DLD-1 (KRAS
mut). NK cells isolated from human PBMCs were cultured
with 1pfu of reovirus for 12 hrs. These reovirus treated
NK cells were co-cultured with DLD-1 cells coated with
increasing concentrations anti-EGFR antibody cetuximab.
ADCC was measured after 4hrs using a lactate dehydro-
genase (LDH) based cytotoxicity assay. We observed that
the reovirus treated NK cells (Reo-NK cells) exhibited a
~16-fold increase in cytotoxicity against DLD-1 (16.3%
±1.5, n=3) compared to untreated NK cells (NK cells),
even in the absence of any cetuximab antibody. In the pre-
sence of cetuximab antibody, NK cells showed a dose
dependent increase in ADCC, with maximum ADCC,
observed at 0.1 µg/ml of cetuximab (DLD-NK: 33.4%± 7.1,
n=3). Interestingly, Reo-NK cells showed maximum
ADCC even at 0.01 µg/ml of cetuximab (DLD1-Reo-NK:
39.1±7.4, DLD1-NK: 26.7±2.4%, n=3).
Results
To further investigate the factors contributing to the
increased cytotoxic potential of Reo-NK cells we performed
flow cytometry analysis to determine the expression of
activation and degranulation markers on NK cells. We
observed that in presence of tumor cells Reo-NK cells
exhibited a 2-fold increased expression of activation marker
CD69 when compared to untreated NK cells (Reo-NK-
70.4%, NK-35.2%). There was a 3-fold increase in expression
of CD107a on Reo-NK cells when compared to NK cells
(Reo-NK: 14.6%; NK: 4.45%). Further, treating Reo-NK and
NK cells with concanamycin A (CMA), an inhibitor of per-
forin, reduced Reo-NK cell mediated ADCC by 3.17 fold
(CMA treated-28.2%, CMA untreated 18.9%) indicating a
perforin-mediated cytotoxicity contributes to the increased
cytotoxicity of Reo-NK cells. Interestingly, UV attenuated
reovirus failed to increase activation and ADCC of NK cells.
Conclusions
Thus, our results demonstrate that reovirus treatement acti-
vated NK cells, and lowered the threshold of cetuximab
required to achieve maximum ADCC.We propose that reo-
virus activated NK cells are a potential candidate for cell
based immunotherapy in combination with FDA approved
tumor targeting antibodies. Further studies are ongoing to
investigate the underlying mechanisms that contribute to the
increase in cytotoxicity by NK cells treated with reovirus.
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